Professor Cliff Bailey and Dr Martin Hadley-Brown provide a 30 minute update on the latest guidance from NICE about SGLT2 inhibitors.
SGLT2 (4/5) – SGLT2 inhibitors: What we need to know from 2021
Professor Cliff Bailey and Dr Martin Hadley-Brown provide a 30 minute update on what you need to know about SGLT2 inhibitors from the 2021 congresses.
SGLT2 (3/5) – SGLT2 inhibitors and the kidney
Professor Cliff Bailey and Dr Pam Brown discuss the Reno-protective effects of SGLT2 inhibitors and the role of SGLT2 inhibitors in the management of diabetic kidney disease.
SGLT2 (2/5) – SGLT2 inhibitors and the heart
Professor Cliff Bailey and Dr Martin Hadley-Brown discuss the effects of SGLT2 inhibitors on cardiovascular function and the role of SGLT2 inhibitors in the management of CV disease.
SGLT2 (1/5) – Understanding SGLT2 inhibition
Professor Cliff Bailey and Professor Vinod Patel assess the clinical evidence and opportunities offered by sodium-glucose co-transporter-2 (SGLT2) inhibitors in the management of type 2 diabetes and its cardio-renal complications.